CDKN2A and astrocytoma (excluding glioblastoma): Several studies have explored the prognostic value of mitotic activity by assessing consecutive high-power fields, revealing worse outcomes for IDH-mutant astrocytomas in the absence of CDKN2A/B HD [18, 39].